BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 32907612)

  • 1. Loss of FBXW7-mediated degradation of BRAF elicits resistance to BET inhibitors in adult T cell leukemia cells.
    Yeh CH; Bellon M; Wang F; Zhang H; Fu L; Nicot C
    Mol Cancer; 2020 Sep; 19(1):139. PubMed ID: 32907612
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oncogenic mutations in the FBXW7 gene of adult T-cell leukemia patients.
    Yeh CH; Bellon M; Pancewicz-Wojtkiewicz J; Nicot C
    Proc Natl Acad Sci U S A; 2016 Jun; 113(24):6731-6. PubMed ID: 27247421
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Colorectal Cancer Stem Cells Acquire Chemoresistance Through the Upregulation of F-Box/WD Repeat-Containing Protein 7 and the Consequent Degradation of c-Myc.
    Izumi D; Ishimoto T; Miyake K; Eto T; Arima K; Kiyozumi Y; Uchihara T; Kurashige J; Iwatsuki M; Baba Y; Sakamoto Y; Miyamoto Y; Yoshida N; Watanabe M; Goel A; Tan P; Baba H
    Stem Cells; 2017 Sep; 35(9):2027-2036. PubMed ID: 28699179
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Loss of FBXW7 and accumulation of MCL1 and PLK1 promote paclitaxel resistance in breast cancer.
    Gasca J; Flores ML; Giráldez S; Ruiz-Borrego M; Tortolero M; Romero F; Japón MA; Sáez C
    Oncotarget; 2016 Aug; 7(33):52751-52765. PubMed ID: 27409838
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting p63 Upregulation Abrogates Resistance to MAPK Inhibitors in Melanoma.
    Patel A; Garcia LF; Mannella V; Gammon L; Borg TM; Maffucci T; Scatolini M; Chiorino G; Vergani E; Rodolfo M; Maurichi A; Posch C; Matin RN; Harwood CA; Bergamaschi D
    Cancer Res; 2020 Jun; 80(12):2676-2688. PubMed ID: 32291316
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recombinant human adenovirus-p53 injection induced apoptosis in hepatocellular carcinoma cell lines mediated by p53-Fbxw7 pathway, which controls c-Myc and cyclin E.
    Tu K; Zheng X; Zhou Z; Li C; Zhang J; Gao J; Yao Y; Liu Q
    PLoS One; 2013; 8(7):e68574. PubMed ID: 23840897
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recent insight into the role of FBXW7 as a tumor suppressor.
    Yumimoto K; Nakayama KI
    Semin Cancer Biol; 2020 Dec; 67(Pt 2):1-15. PubMed ID: 32113998
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FBXW7: a critical tumor suppressor of human cancers.
    Yeh CH; Bellon M; Nicot C
    Mol Cancer; 2018 Aug; 17(1):115. PubMed ID: 30086763
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The FBXW7-NOTCH interactome: A ubiquitin proteasomal system-induced crosstalk modulating oncogenic transformation in human tissues.
    Kar R; Jha SK; Ojha S; Sharma A; Dholpuria S; Raju VSR; Prasher P; Chellappan DK; Gupta G; Kumar Singh S; Paudel KR; Hansbro PM; Kumar Singh S; Ruokolainen J; Kesari KK; Dua K; Jha NK
    Cancer Rep (Hoboken); 2021 Aug; 4(4):e1369. PubMed ID: 33822486
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Loss of Fbxw7 triggers mammary tumorigenesis associated with E2F/c-Myc activation and Trp53 mutation.
    Meyer AE; Furumo Q; Stelloh C; Minella AC; Rao S
    Neoplasia; 2020 Nov; 22(11):644-658. PubMed ID: 33070870
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regulation of BRAF protein stability by a negative feedback loop involving the MEK-ERK pathway but not the FBXW7 tumour suppressor.
    Hernandez MA; Patel B; Hey F; Giblett S; Davis H; Pritchard C
    Cell Signal; 2016 Jun; 28(6):561-71. PubMed ID: 26898828
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FBXW7 tumor suppressor regulation by dualspecificity tyrosine-regulated kinase 2.
    Jiménez-Izquierdo R; Morrugares R; Suanes-Cobos L; Correa-Sáez A; Garrido-Rodríguez M; Cerero-Tejero L; Khan OM; de la Luna S; Sancho R; Calzado MA
    Cell Death Dis; 2023 Mar; 14(3):202. PubMed ID: 36934104
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-Resolution Mapping of RNA Polymerases Identifies Mechanisms of Sensitivity and Resistance to BET Inhibitors in t(8;21) AML.
    Zhao Y; Liu Q; Acharya P; Stengel KR; Sheng Q; Zhou X; Kwak H; Fischer MA; Bradner JE; Strickland SA; Mohan SR; Savona MR; Venters BJ; Zhou MM; Lis JT; Hiebert SW
    Cell Rep; 2016 Aug; 16(7):2003-16. PubMed ID: 27498870
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Involvement of MCL1, c-myc, and cyclin D2 protein degradation in ponatinib-induced cytotoxicity against T315I(+) Ph+leukemia cells.
    Inoue C; Sobue S; Kawamoto Y; Nishizawa Y; Ichihara M; Abe A; Hayakawa F; Suzuki M; Nozawa Y; Murate T
    Biochem Biophys Res Commun; 2020 May; 525(4):1074-1080. PubMed ID: 32184020
    [TBL] [Abstract][Full Text] [Related]  

  • 15. E3 ligase FBXW7 restricts M2-like tumor-associated macrophage polarization by targeting c-Myc.
    Zhong L; Zhang Y; Li M; Song Y; Liu D; Yang X; Yang D; Qu H; Lai L; Wang Q; Chen Z
    Aging (Albany NY); 2020 Dec; 12(23):24394-24423. PubMed ID: 33260160
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Niclosamide, an anti-helminthic molecule, downregulates the retroviral oncoprotein Tax and pro-survival Bcl-2 proteins in HTLV-1-transformed T lymphocytes.
    Xiang D; Yuan Y; Chen L; Liu X; Belani C; Cheng H
    Biochem Biophys Res Commun; 2015 Aug; 464(1):221-228. PubMed ID: 26116531
    [TBL] [Abstract][Full Text] [Related]  

  • 17.
    Tong J; Tan S; Nikolovska-Coleska Z; Yu J; Zou F; Zhang L
    Mol Cancer Ther; 2017 Sep; 16(9):1979-1988. PubMed ID: 28619760
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overcoming BRAF and CDK4/6 inhibitor resistance by inhibiting MAP3K3-dependent protection against YAP lysosomal degradation.
    Park S; Ryu WJ; Kim TY; Hwang Y; Han HJ; Lee JD; Kim GM; Sohn J; Kim SK; Kim MH; Kim J
    Exp Mol Med; 2024 Apr; 56(4):987-1000. PubMed ID: 38622197
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rictor regulates FBXW7-dependent c-Myc and cyclin E degradation in colorectal cancer cells.
    Guo Z; Zhou Y; Evers BM; Wang Q
    Biochem Biophys Res Commun; 2012 Feb; 418(2):426-32. PubMed ID: 22285861
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ATL response to arsenic/interferon therapy is triggered by SUMO/PML/RNF4-dependent Tax degradation.
    Dassouki Z; Sahin U; El Hajj H; Jollivet F; Kfoury Y; Lallemand-Breitenbach V; Hermine O; de Thé H; Bazarbachi A
    Blood; 2015 Jan; 125(3):474-82. PubMed ID: 25395419
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.